Market cap
$564 Mln
Revenue (TTM)
$519 Mln
P/E Ratio
24.1
P/B Ratio
2.1
Div. Yield
0.3 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 2.31 | -4.26 | 0.35 | 0.61 | 3.07 |
| EBIT | 384.95 | -40.15 | -10.97 | -4.61 | -0.07 |
| Net Profit | 841.09 | -42.34 | -17.35 | -15.13 | -10.23 |
| EPS | 841.92 | -43.25 | -16.48 | -14.68 | -6.20 |
| Book Value | -- | -- | 8.44 | 13.28 | 29.17 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| 10.87 | 10.14 | 9.21 | 10.72 | 11.18 |
| Net Margin
| -- | -- | 4.69 | -- | -- |
| Return on equity
| 14.19 | 14.26 | 8.91 | 11.46 | 13.17 |
| Return on Capital
| 7.58 | 6.49 | -- | 6.88 | 7.20 |
| Return on Assets
| 5.56 | 4.70 | 3.49 | 5.05 | 5.34 |
| Debt to Equity (x)
| -- | -- | 0.42 | 0.62 | 0.71 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
--
|
6.88
|
7.20
|
8.66
|
4.78
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
8.91
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
8.91
|
11.46
|
13.17
|
17.93
|
11.42
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
3.49
--
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
3.49
|
5.05
|
5.34
|
6.30
|
3.36
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
9.21
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
9.21
|
10.72
|
11.18
|
10.72
|
8.48
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
4.69
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
4.69
|
5.63
|
5.99
|
7.19
|
3.97
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
0.35
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
0.35
|
0.01
|
0.03
|
0.04
|
0.04
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
-10.97
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
-10.97
|
-3.57
|
7.17
|
31.59
|
-8.26
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
-17.35
--
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
-17.35
|
-5.51
|
-14.38
|
88.53
|
-1.39
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
-16.48
--
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
-16.48
|
-0.03
|
-0.15
|
0.86
|
-0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Book Value Growth
5.76
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
5.76
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.42
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
0.42
|
0.62
|
0.71
|
0.96
|
1.21
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.04
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
0.04
|
0.04
|
0.04
|
0.05
|
0.06
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.12
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
2.12
|
2.02
|
2.32
|
2.53
|
2.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
1.55
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
1.55
|
1.51
|
1.71
|
1.72
|
1.47
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
4.35
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
4.35
|
5.34
|
4.73
|
4.07
|
3.59
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
22.36
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
22.36
|
22.94
|
24.31
|
24.14
|
23.50
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.74
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
0.74
|
0.90
|
0.89
|
0.88
|
0.84
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
--
|
86.07
|
87.30
|
85.32
|
82.73
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
--
|
48.12
|
54.98
|
58.05
|
47.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
--
|
30.35
|
28.54
|
34.86
|
33.60
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
--
|
103.85
|
113.74
|
108.51
|
96.20
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
24.10
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
24.10
|
25.12
|
26.34
|
22.90
|
48.79
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
2.13
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
2.13
|
2.80
|
3.28
|
3.74
|
5.15
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Dividend Yield
0.32
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
0.32
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
11.54
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
11.54
|
12.47
|
13.44
|
14.77
|
19.70
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
564
--
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Core Laboratories NV (CLB)
|
564
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|